CTLA4 and cancer: Immune checkpoint inhibitors are a recent class of anticancer drugs that enhance the adaptive immune response by blocking the inhibitory binding between specific T-cell receptors (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and their ligands, which are overexpressed in cancer cells [73].